Metzelder, S K; Schroeder, T; Lübbert, M; Ditschkowski, M; Götze, K; Scholl, S; Meyer, R G; Dreger, P; Basara, N; Fey, Martin; Salih, H R; Finck, A; Pabst, Thomas; Giagounidis, A; Kobbe, G; Wollmer, E; Finke, J; Neubauer, A; Burchert, A (2017). Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation. European journal of cancer, 86, pp. 233-239. Elsevier 10.1016/j.ejca.2017.09.016
![[img]](https://boris.unibe.ch/style/images/fileicons/text.png) |
Text
1-s2.0-S0959804917312972-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (620kB) |
BACKGROUND
Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD)-positive acute myeloid leukaemia (AML) relapsing after allogeneic stem cell transplantation (allo-SCT) has a dismal prognosis with limited therapeutic options. FLT3-ITD kinase inhibition is a reasonable but palliative experimental treatment alternative in this situation. Information on long-term outcome is not available.
METHODS
We performed a long-term follow-up analysis of a previously reported cohort of 29 FLT3-ITD-positive AML patients, which were treated in relapse after allo-SCT with sorafenib monotherapy.
FINDINGS
With a median follow-up of 7.5 years, 6 of 29 patients (21%) are still alive. Excluding one patient who received a second allo-SCT, five patients (17%) achieved sustained complete remissions with sorafenib. Four of these patients are in treatment-free remission for a median of 4.4 years.
INTERPRETATION
Sorafenib may enable cure of a proportion of very poor risk FLT3-ITD-positive AML relapsing after allo-SCT.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology |
UniBE Contributor: |
Fey, Martin, Pabst, Thomas Niklaus |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0959-8049 |
Publisher: |
Elsevier |
Language: |
English |
Submitter: |
Nicole Corminboeuf |
Date Deposited: |
21 Feb 2018 11:23 |
Last Modified: |
02 Mar 2023 23:30 |
Publisher DOI: |
10.1016/j.ejca.2017.09.016 |
PubMed ID: |
29055209 |
Uncontrolled Keywords: |
Acute myeloid leukemia FLT3-ITD Hematopoietic stem cell transplantation Sorafenib |
BORIS DOI: |
10.7892/boris.111188 |
URI: |
https://boris.unibe.ch/id/eprint/111188 |
Actions (login required)
 |
Edit item |